Skip to main content
OpenTrials
Completed

NCT Number: NCT04271371

Preventing Relapse to Smoking Among Prisoners After Release

Prisoners experience huge health inequalities, and their exceptionally high smoking prevalence (five times the national average) contributes significantly to their high mortality. Since the introduction of smoke-free polices across Her Majesty's Prison and Probation Service (HMPPS) in England and Wales, prisoners are now obliged to abstain from smoking while held in prison. This represents a unique opportunity to promote lifelong cessation in this highly disadvantaged and marginalised group. However, evidence suggests most prisoners intend to resume smoking as soon as possible after release. A systematic review of prison smoke-free polices worldwide concluded that there was a need for new research to identify effective strategies to reduce relapse in these individuals.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Observational

Primary location

University of Nottingham, School of Medicine

Nottingham, Please Select, NG5 1PB, United Kingdom

About this study

The primary objective of this study will be to develop and pilot test the feasibility and acceptability of an intervention to help prevent prisoners relapse to smoking after release. The study will work in accordance with the Medical Research Council (MRC) framework for developing and evaluating complex interventions. The Preventing Relapse tO Smoking among PrisonErs after Release (PROSPER) study consists of three key Phases:

  • Document the support provided to manage nicotine addiction during imprisonment and in the periods immediately before and after release; establish the extent to which prisoners intentionally resume or unintentionally relapse to smoking after release; and obtain views on how relapse might be prevented.
  • Drawing on current literature and findings from Phase 1, develop and design an prototype intervention to prevent smoking relapse after release.
  • To pilot the designed prototype intervention and conduct a process evaluation to inform the development of further work in this area.

The research will be carried out in three prisons in the East Midlands. The main duties will include recruitment of participants (HMPPS staff members and prisoners), data collection, data analysis, assist with intervention development and refining related intervention materials/resources, co-facilitate Patient and Public Involvement (PPI) groups, contribute to the ethical application for the pilot intervention, and preparation of manuscripts for peer-review publication.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

2. Release prisoner cohort

  • All participants are aged 18 or over (no upper age limit)
  • Are currently residing in one of the three study sites (HMPs Nottingham, Ranby and Sudbury)
  • Male (women will not be held at any of the study sites)
  • Have a provisional release date within the next 2 months.
  • Are capable of understanding and consenting to the study.
  • Remand and sentenced prisoners.
  • Who report that they are a current smoker and/or a current smoker prior to entering prison (smoked up to 7 days before entering prison), and/or were in prison (and still on the same sentence) and a current smoker prior to the smoke-free prison policy.
  • Reception prisoner cross-sectional
  • All participants are aged 18 or over (no upper age limit)
  • Are currently residing in the open prison study site (HMP Sudbury)
  • Male (women will not be held at any of the study sites)
  • Have been in the open prison more than two weeks but for less than 3 months.
  • Have been transferred from a closed prison.
  • Are capable of understanding and consenting to the study.
  • Sentenced prisoners.
  • Who report that they were a current smoker prior to entering prison (smoked up to 7 days before entering prison), and/or were in prison (and still on the same sentence) and a current smoker prior to the smoke-free prison policy.

Exclusion criteria

2. Release prisoner cohort

  • Present a serious risk of harm to the researchers, highlighted in PNOMIS records or by a member of staff.
  • Non-smokers.
  • Being deported post release.
  • Been in prison for less than four weeks.
  • Reception prisoner cross-sectional
  • Present a serious risk of harm to the researchers, highlighted in PNOMIS records or by a member of staff.
  • Been in prison for less than 2 weeks.
  • Non-smokers.

Treatment and study plan

Not yet developed

Other

A prototype intervention will be developed over Phase 1 & 2 and piloted in Phase 3 of this study.

Primary outcomes

  1. To develop and pilot test the feasibility and acceptability of an intervention to help prevent prisoners relapse to smoking after release.

    Time frame: 3 years

    Smoking abstinence rates at 1 week, 1 month and 3 months post release, self-reported.

Secondary outcomes

  1. To document prisoners smoking history to date and levels of nicotine addiction.

    Time frame: 1 year

    Phase 1 (Scoping stakeholder interviews/Release prisoner cohort/Reception prisoner cross-sectional)

  2. To document the support provided to manage nicotine addiction during imprisonment and in the periods immediately before and after release.

    Time frame: 1 year

    Phase 1 (Scoping stakeholder interviews/Release prisoner cohort/Reception prisoner cross-sectional)

  3. The impact of smoke-free prison policy on prisoners smoking behaviours.

    Time frame: 1 year

    Phase 1 (Scoping stakeholder interviews/Release prisoner cohort/Reception prisoner cross-sectional)

  4. To establish the extent to which prisoners intentionally resume or unintentionally relapse to smoking after release (and does their intended behaviour pre-release predict post-release behaviour).

    Time frame: 1 year

    Phase 1 (Scoping stakeholder interviews/Release prisoner cohort/Reception prisoner cross-sectional)

  5. To establish the extent to which prisoners relapse to smoking after transfer to an open prison where smoking is permitted in designated areas.

    Time frame: 1 year

    Phase 1 (Scoping stakeholder interviews/Release prisoner cohort/Reception prisoner cross-sectional)

  6. To obtain views on triggers to smoking after release (and transfer to an open prison) and how relapse might be prevented.

    Time frame: 1 year

    Phase 1 (Scoping stakeholder interviews/Release prisoner cohort/Reception prisoner cross-sectional)

  7. For those prisoners who return to smoking after release, at what point do they resume smoking (in days).

    Time frame: 1 year

    Phase 1 (Scoping stakeholder interviews/Release prisoner cohort/Reception prisoner cross-sectional)

  8. After release do prisoners use cessation pharmacotherapy, electronic cigarettes or NHS SSS support, or any other means of preventing relapse.

    Time frame: 1 year

    Phase 1 (Scoping stakeholder interviews/Release prisoner cohort/Reception prisoner cross-sectional)

  9. Record and examine other potential predictors (as outlined in the international literature) of relapse to smoking after release from smoke-free prisons, e.g other negative health behaviours.

    Time frame: 1 year

    Phase 1 (Scoping stakeholder interviews/Release prisoner cohort/Reception prisoner cross-sectional)

  10. For those prisoners who do return to smoking after release, do they smoke less, the same or more as they previously smoked before entering prison/and or before the prison service went smoke-free.

    Time frame: 1 year

    Phase 1 (Scoping stakeholder interviews/Release prisoner cohort/Reception prisoner cross-sectional)

  11. Review of methods of recruitment in prison and community follow-up (to feed into future pilot intervention study).

    Time frame: 1 year

    Phase 1 (Scoping stakeholder interviews/Release prisoner cohort/Reception prisoner cross-sectional)

  12. To develop, design, and refine an intervention to prevent smoking relapse after release with input from fellow academics, stakeholders and PPI groups.

    Time frame: 1 year

    Phase 2 (Intervention development)

  13. To develop logic models to map the problem and the prototype intervention.

    Time frame: 1 year

    Phase 2 (Intervention development)

  14. To assess any barriers and facilitators to the developed intervention.

    Time frame: 1 year

    Phase 3 (Intervention pilot & Intervention process evaluation)

  15. To explore any unintended consequences as a result of the intervention.

    Time frame: 1 year

    Phase 3 (Intervention pilot & Intervention process evaluation)

  16. To identify aspects of the intervention and delivery that could be improved.

    Time frame: 1 year

    Phase 3 (Intervention pilot & Intervention process evaluation)

  17. Explore smoking abstinence rates at 1 week, 1 month and 3 months post release, self-reported and CO validated.

    Time frame: 1 year

    Phase 3 (Intervention pilot & Intervention process evaluation)

  18. Explore impact of the intervention on self-reported health, housing, reconviction rates, use of illicit substances in prisoner's post- release.

    Time frame: 1 year

    Phase 3 (Intervention pilot & Intervention process evaluation)

Sponsors and collaborators

Lead sponsor

University of Nottingham

Other

Collaborators

  • Cancer Research UK
  • Her Majesty's Prison and Probation Service (HMPPS)
  • Plymouth University Peninsula Schools of Medicine & Dentistry (PUPSMD)
  • Public Health England

Registry information

Official study title

Preventing Relapse to Smoking Among Prisoners After Release: Developing and Piloting a Complex Health Intervention

Acronym: PROSPER

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Feb 17, 2020
Registry last updated
Feb 28, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.